The global MRI-guided neurosurgical ablation market is valued at USD 172.89 million in 2025 and is poised to reach USD 234.62 million by 2035, which shows a CAGR of 3.1%. This growth is driven by the increasing demand for minimally invasive procedures, which offer faster recovery times, fewer complications, and improved patient outcomes.
MRI-guided neurosurgical ablation has gained popularity due to its precision in targeting and ablating tissue, making it an ideal solution for treating various neurological conditions. The rise in neurological disorders such as brain tumors, epilepsy, and movement disorders further propels the demand for advanced techniques like MRI-guided ablation, especially for patients seeking safer alternatives.
Looking ahead, the market for MRI-guided neurosurgical ablation is likely to continue its growth in the coming years, supported by ongoing technological advancements and the increased adoption of minimally invasive procedures. With enhancements in MRI technology, including higher-resolution imaging and improved tissue differentiation, the precision and effectiveness of neurosurgical ablation are expected to improve.
Additionally, the trend toward outpatient procedures and shorter recovery times is likely to drive more healthcare providers to adopt MRI-guided techniques. Moreover, ongoing clinical trials exploring the broader use of MRI-guided ablation for a range of neurological conditions are expected to expand the technology’s applications, contributing to market growth as well as improving patient outcomes.
Government regulations play a vital role in shaping the MRI-guided neurosurgical ablation market. Regulatory bodies like the USA. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce strict guidelines to ensure the safety and efficacy of medical devices. These regulations guarantee that MRI-guided systems meet safety standards and perform as intended. As the technology evolves, regulatory bodies are likely to continue updating their standards to address new innovations and emerging risks, helping to maintain patient safety and driving further growth in the market.
The below table presents the expected CAGR for the global MRI guided neurosurgical ablation market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 4.2%, followed by a slightly lower growth rate of 3.8% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 (2024 to 2034) | 4.2% |
| H2 (2024 to 2034) | 3.8% |
| H1 (2025 to 2035) | 3.1% |
| H2 (2025 to 2035) | 2.7% |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 3.1% in the first half and remain relatively moderate at 2.7% in the second half. In the first half (H1) the market witnessed a decrease of 110 BPS while in the second half (H2), the market witnessed a decrease of 110 BPS.
The market is segmented based on product, treatment type, end user, and region. By product type, the market is divided into MRI guided laser therapy systems, MRI guided focused ultrasound systems, and accessories. In terms of treatment type, it is segmented into brain metastases, radiation necrosis, glioma, epilepsy, and other treatments (such as Meningioma, acoustic neuroma, cerebral aneurysm, and traumatic brain injury).
Based on end user, the market is categorized into hospitals, cancer treatment centers, specialized surgical centers (neurology and neurosurgery centers), and academic & research institutes. Regionally, the market is classified into North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa.
The MRI guided laser therapy systems segment is expected to grow at the highest CAGR of 7.4% from 2025 to 2035. This growth is fueled by the increasing demand for minimally invasive procedures in neurosurgery. MRI guided laser therapy systems offer precise targeting of brain tumors and lesions, reducing damage to surrounding tissues. These systems are especially beneficial in treating difficult-to-reach areas, such as deep-seated gliomas and brain metastases, making them a popular choice for both surgeons and patients seeking effective, less invasive options.
As healthcare continues to prioritize patient safety and faster recovery, the demand for MRI guided laser therapy systems is set to surge. The technology’s ability to deliver high precision while minimizing the need for invasive procedures is increasing its adoption across hospitals and specialized centers. Additionally, these systems are effective in treating conditions that were previously difficult to address through traditional surgical methods.
Meanwhile, MRI guided focused ultrasound systems, though slower in growth, continue to hold a significant share of the market due to their non-invasive approach and ability to treat tumors without incisions. Accessories required for MRI guided procedures also witness steady demand, though their growth is comparatively slower than that of the primary products.
The brain metastases segment is projected to grow at the highest CAGR of 6.8% from 2025 to 2035. This is largely due to the increasing prevalence of metastatic cancers, coupled with the rising emphasis on non-invasive treatment methods. With the growing number of cancer patients and advancements in targeted therapies, MRI guided treatments are becoming vital in improving survival rates and enhancing the quality of life for patients with brain metastases.
Non-invasive techniques, such as MRI guided laser therapy, are highly effective in treating tumors in the brain, offering precision while minimizing collateral damage to healthy tissues. This has resulted in a surge in demand for such treatments. Meanwhile, treatments for radiation necrosis and glioma continue to dominate both by volume and value, as they have widespread applications in brain cancer treatment. Epilepsy treatments, while experiencing steady demand, do not see the rapid growth that other segments do, although there remains a consistent need for effective management options.
The other treatments category, including conditions like meningioma and acoustic neuroma, continues to witness gradual growth as ongoing research and advancements in medical technologies improve treatment outcomes. As the healthcare industry continues to focus on early diagnosis and more effective treatment methods, the demand for these therapies is expected to rise steadily.
The hospitals segment is expected to hold a dominant 45% share of the MRI guided neurosurgical ablation market and grow at the fastest rate due to the increasing demand for advanced treatment options in neurosurgery. Hospitals offer comprehensive neurosurgical services, with MRI-guided therapy systems being a key part of their treatment offerings for brain tumors, metastases, and other neurological disorders.
The growing shift toward minimally invasive surgeries, as well as patient-centric care models, is accelerating the adoption of these technologies in hospital settings. MRI-guided treatments offer precision while also reducing recovery times, which is a crucial factor in the growing preference for minimally invasive procedures in hospitals. Additionally, hospitals are at the forefront of integrating the latest technological advancements in medical devices, making them the primary end-user for MRI-guided neurosurgical treatments.
Cancer treatment centers are also experiencing steady demand, driven by the increasing number of cancer patients requiring specialized care for brain metastases and central nervous system cancers. These centers focus on advanced therapies like MRI-guided laser therapy, which enhances patient outcomes. Specialized surgical centers, including neurology and neurosurgery centers, are seeing a rise in market share due to their focus on specialized treatments for neurological conditions. Academic and research institutes continue to contribute to the development of innovative technologies, supporting market growth.
Rising Incidence of Drug-Resistant Epilepsy has fueled the MRI Guided Neurosurgical Ablation Market growth
Drug Resistant epilepsy is characterized by the continuous seizure episode even after the treatment by antiepileptic drugs. Since the traditional treatment fail to stop seizure episode there is need for alternative method such as MRI-guided ablation.
MRI-guided neurosurgical ablation is a minimal invasive procedure used for drug-resistant epilepsy. Real-time MRI imaging makes accurate delivery of ablation possible, targeting only the epileptic tissue of the brain. It reduced the damage to the surrounding area. This is particularly beneficial for the treatment of deep-seated foci in the brain or other inaccessible locations due to anatomical constraints in drug-resistant epilepsy patients.
Clinical studies reflect an advanced outcome for patients with drug-resistant epilepsy. For example, the capability of LITT to reduce seizures as high as 60-70% in cases makes this one promising treatment option for patients running out of pharmaceutical options. With every additional drug-resistant epilepsy case, healthcare providers seek to utilize more advanced techniques for the improvement of the patient outcome and quality of life.
One of the more common reasons for applying MRI-guided neurosurgical ablation is the increasingly diagnosed incidence of drug-resistant epilepsy, which comprises approximately 11-41% of all epilepsies. Hence, all the aforementioned factor contributes to the market growth.
Increased Preference for Minimal Invasive Procedures drives demand for MRI Guided Neurosurgical Ablation
Minimally invasive procedures work in favor of the patient, mainly because of reduced recovery time, lowered risk of complications, and minimal scarring, and has gained tremendous momentum in modern healthcare. This is specifically pertinent to neurosurgery, because precision and minimal damage to surrounding brain tissue are critical.
MRI-guided neurosurgical ablation, particularly LITT, is among the leaders of this new wave. It enables surgeons to make highly targeted interventions within the brain under real-time imaging using MRI while ablating offending tissue without significant disruption to intact areas.
Patients stay for less time in the hospital, recover speedily, and have fewer complications following surgery. For instance, the studies have demonstrated that LITT procedures normally require a 1 to 2 day hospital stay; however, conventional procedures normally take up to 5 to 7 days.
There is an increasing need for minimally invasive procedures in this arena, especially concerning neurological disease treatment, where high accuracy and precision are required. Patients will shift more towards MRI-guided ablation because of the advantages it brings about, like reduced trauma and fast recovery, which fuel acceptance of such technologies in neurosurgery.
The growing and aggressive demand for MIS is therefore a significant driving force for the market demand for MRI-guided neurosurgical ablation of neurological disorders such as epilepsy, brain tumors, and movement disorders.
Expanding Insurance Coverage for MRI-guided neurosurgical ablation procedures provides an Opportunity for Market Growth
Expanding insurance coverage for MRI-guided neurosurgical ablation procedures is increasing growth opportunities within the market. As more insurance companies start acknowledging the clinical efficacy and eventual long-term savings of such minimally invasive treatments, more patients and healthcare institutions are being facilitated in accessing better technology such as MRI-guided focused ultrasound (MRgFUS) and laser ablation therapies, thus eradicating the barriers that have traditionally limited such procedures' wide adoption.
In February 2024, Anthem Blue Cross and Blue Shield (BCBS) announced coverage for the innovative focused ultrasound pallidotomy procedure. This follows a January 2024 announcement from Insightec, stating that approximately 9.5 million members of the USA military and their dependents under Tricare would receive reimbursement for treating essential tremor with focused ultrasound.
Additionally, in November 2023, Monteris Medical revealed that Aetna had updated its medical policy. This update extends coverage to beneficiaries affected by recurrent brain metastases, radiation necrosis, and recurrent glioblastoma. The inclusion of insurance coverage for MRI-guided neurosurgical ablation procedures is expected to enhance adoption rates among healthcare providers, as it lowers financial barriers for patients.
High Initial Costs of Equipment and Procedures Hinder the Market Growth
Highly advanced, minimally invasive MRI-guided technologies are MRI-guided focused ultrasound (MRgFUS) and laser interstitial thermal therapy (LITT). Such systems are expensive to acquire, install, and maintain, and therefore may be unaffordable for medium and small healthcare facilities as well as those located in developing regions.
Having MRI technology in place is a prerequisite for adopting the MRI-guided procedure. This limits the number of potential customers who may embrace the equipment. Not to mention, the MRI Machine is an expensive one on its cost. Apart from the MRI equipment itself, specific ablation systems such as focused ultrasound or laser ablation devices add an even further cost burden on the top.
These systems are based on MRI hardware and software combinations, which demands complex hardware and software integration for functionality in unison with the MRI machines, making them costly altogether. Moreover, they usually demand one of the specialized operating rooms, known as MRI-compatible surgical suites, which also adds extra cost due to the need for infrastructure changes.
The maintenance costs for MRI-guided systems are also high. It is a must to service the MRI machines and ablation devices annually to ensure that these instruments function accurately and give out the results correctly. Hence higher equipment and procedure costs restrain the growth of the MRI-guided neurosurgical ablation market.
The MRI guided neurosurgical ablation industry recorded a CAGR of 2.3% between 2019 and 2023. According to the industry, MRI guided neurosurgical ablation generated USD 163.14 million in 2023, up from USD 148.80 million in 2019.
Traditionally, this market was associated with limited adoption, due to technological limitations and the procedural expense. Things changed when MRI-guided LITT, at the early 2000s, came to become the first therapy to enter the space of brain tumors and epilepsy to prove that the minimally invasive approaches were indeed feasible. There was gradual growth as healthcare providers began recognizing the benefits of MRI guidance in enhancing surgical precision and patient outcomes.
Currently, the market is experiencing robust growth due to the growing prevalence of neurological disorders, including brain tumors. There is a strong trend towards minimally invasive surgical techniques primarily because of developments in MRI technology where the current imaging is more real-time and procedures are accurate. Brain health awareness, which is also growing, and the higher acceptability of insurance reimbursement has been resulting in an increasing number of hospitals adopting these technologies.
Future innovations in the market are supposed to include incorporation of artificial intelligence towards better treatment planning and outcomes. The development of high-intensity focused ultrasound (HIFU) devices is anticipated to expand treatment options. With the rise patient centric care the market for MRI guided neurosurgical ablation is expected to increase.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 65.6% in global market. These market leaders are distinguished by their consumer base. They provide a state of the art manufacturing of medical device utilizing the latest technology and meeting the regulatory standards providing the highest quality. Prominent companies within tier 1 include Medtronic plc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 32.3% market share. These are characterized by a strong presence overseas and strong market knowledge. These market players have good technology and ensure regulatory compliance but may not have advanced technology and global reach. Prominent companies in tier 2 include Insightec and Monteris Medical Inc. etc.
Finally, Tier 3 companies, has limited market presence. These companies are improving the local presence and establishing partnership with distributor within other country to increase their global presence as well.
The section below covers the industry analysis for the MRI guided neurosurgical ablation market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA), is provided. The United States is anticipated to remain at the forefront in North America through 2034 in terms of market size. India is projected to witness a CAGR of 5.6% from 2025 to 2035.
In terms of product, the industry is segmented into MRI guided laser therapy systems, MRI guided focused ultrasound systems, and accessories.
In terms of treatment types, the industry is bifurcated into brain metastases, radiation necrosis, glioma, epilepsy, and other treatments.
In terms of end use, the industry is segregated into hospitals, cancer treatment centers, specialized surgical centers (neurology and neurosurgery centers), and academic & research institutes.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, the Middle East, and Africa have been covered in the report.
The global market is expected to reach USD 234.62 million by 2035, growing from USD 172.89 million in 2025, at a CAGR of 3.1%.
The MRI guided laser therapy systems segment is projected to grow at the fastest pace, registering a CAGR of 7.4%.
The brain metastases segment is expected to grow at the fastest rate, with a CAGR of 6.8%.
Key drivers include increasing neurological disorders, the shift to minimally invasive procedures, and advancements in MRI technology.
Top companies include Medtronic plc, Insightec, Monteris Medical Inc., and ClearPoint Neuro, Inc.
Explore Similar Insights
MRI Guided Neurosurgical Ablation Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
